Objective: To investigate the clinical efficacy of somatostatin in the treatment of acute lymphoblastic leukemia children with pegaspargase associated pancreatitis. Methods: From Jan. 2015 to Jan. 2017

a total of 13 children with acute lymphoblastic leukemia who developed pegaspargase associated pancreatitis after chemotherapy of CCCG-2015 regimen in our hospital were selected. Children were treated with somatostatin after diagnosis of pegaspargase associated pancreatitis. Disappearance time of abdominal tenderness

blood amylase

blood lipase and recovery time of imaging were observed. Results: The symptoms of abdominal pain in 13 children were relieved. One child was necrotizing pancreatitis with severe shock accompanied by abdominal secondary infection. After treatment of anti-infection and fluid infusion

the child was transferred to surgery for surgical drainage and recovered. After treatment

children’s biochemical indicators such as blood amylase and lipase were significantly reduced. Conclusion: The efficacy of somatostatin in the treatment of acute lymphoblastic leukemia children with pegaspargase associated pancreatitis is significant

which can effectively relieve patient’s abdominal pain and biochemical indicators. It is worthy of clinical application.